Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2‐positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Issue 1 (24th June 2019)

• Record Type: Journal Article
• Authors: Liu, Tianshu; Qin, Yanru; Li, Jin; Xu, Ruihua; Xu, Jianming; Yang, Shujun; Qin, Shukui; Bai, Yuxian; Wu, Changping; Mao, Yixiang; Wu, Haiyan; Ge, Yilin; Shen, Lin
• Is Part Of: Cancer communications. Volume 39:Issue 1(2019)
• Page Start: 1
• Page End: 10
• Publication Date: 2019-06-24
• Subjects: Gastric cancer -- Gastroesophageal junction cancer -- HER2 -- Pertuzumab -- Trastuzumab -- Chemotherapy -- Overall survival -- Progression‐free survival -- Safety -- China; Cancer -- Periodicals; Neoplasms; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 616.994005
• DOI: 10.1186/s40880-019-0384-6
• Languages: English
• ISSNs: 2523-3548

Abstract

Abstract: Background: The JACOB trial (NCT01774786) was a double‐blinded, placebo‐controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemotherapy in first‐line treatment of human epidermal growth factor receptor 2 (HER2)‐positive metastatic gastric cancer/gastroesophageal junction cancer (GEJC). The aim of this analysis was to investigate efficacy and safety outcomes in the Chinese subpopulation from the JACOB trial. Methods: This post hoc subpopulation analysis included all patients recruited in mainland China ( n = 163; 20.9%) between June 2013 and January 2016. The patients were randomly assigned in a 1:1 ratio to receive pertuzumab plus trastuzumab and chemotherapy (pertuzumab group; n = 82) or placebo plus trastuzumab and chemotherapy (control group; n = 81). Intravenous pertuzumab (840 mg) and trastuzumab (8 mg/kg loading and 6 mg/kg maintenance doses) were given every 3 weeks until disease progression or unacceptable toxicity. Chemotherapy was given as per standard regimens/doses of capecitabine or 5‐fluorouracil plus cisplatin. The primary endpoint was overall survival (OS); secondary efficacy endpoints included progression‐free survival (PFS), and overall objective response rate (ORR). Results: The median OS was 18.7 months in the pertuzumab group and 16.1 months in the control group (hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.49 to 1.14). The median PFS was 10.5 and 8.6 months in the pertuzumab and control groups, respectively (HR 0.85; 95% CI 0.60 to 1.21), and the median ORRs were 68.9% and 55.7%, respectively. The treatment effect in this Chinese subpopulation showed consistency with that in the global ITT population with numerically lower HR for OS and PFS compared with the control group. The safety profiles of the pertuzumab and control groups in this Chinese subpopulation analysis were generally comparable. The most common grade 3–5 adverse events were neutropenia, anemia, and leukopenia. However, due to the nature of being a post hoc subgroup analysis, the results presented here are descriptive only and need to be interpreted with caution. Conclusions: OS and PFS were numerically improved by adding pertuzumab to trastuzumab and chemotherapy as first‐line treatment in Chinese HER2‐positive gastric cancer/GEJC patients, and this regimen demonstrated an acceptable safety profile. Trial registration ClinicalTrials.gov . NCT01774786. Registered on 24 January 2013, https://clinicaltrials.gov/ct2/show/NCT01774786